Giant cell bone
tumors (osteoclastoma, myeloplax tumor) are benign
tumors, although they are locally aggressive. They
represent between 5% and 7% of primary bone tumors.
The most common occurrence sites are near joints
(commonly the knee joint) involving the ends of long
bones: proximal tibia, distal femur, distal radius.
The onset age of the disease is between twenty and
thirty years, with a slight predominance of the
female gender. The diagnosis is based on clinical
examination, X-rays of the bone, CT and MRI. Some
authors suspected an angiogenetic origin of the
tumor and another possible factor in the etiology is
genetic predisposition. Giant cells arise by
transformation of circulating monocytes, many of
them later becoming active osteoclasts.
A rare complication
of these tumors, but with high lethal potential, is
the malignant transformation (primary and secondary
malignancies). The best treatment is surgery, with
or without area reconstruction. Another therapeutic
method is cryosurgery. In the treatment of tumor
metastasis (commonly occurring in the lungs),
chemotherapy and surgery are indicated.
Key words: bone
tumor, giant cells, locally aggressive, metastasis,
circulating monocytes, surgery.